On Oct 08, major Wall Street analysts update their ratings for $Zenas BioPharma (ZBIO.US)$, with price targets ranging from $27 to $40.
Morgan Stanley analyst Vikram Purohit initiates coverage with a buy rating, and sets the target price at $40.
Citi analyst Yigal Nochomovitz initiates coverage with a buy rating, and sets the target price at $27.
Jefferies analyst Roger Song initiates coverage with a buy rating, and sets the target price at $35.
Guggenheim analyst Yatin Suneja initiates coverage with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Zenas BioPharma (ZBIO.US)$'s main analysts recently are as follows:
Zenas BioPharma's obexelimab is seen as a significant asset within its portfolio, poised to address various conditions within the inflammation and immunology category. The primary indication, IgG4-RD, is at the forefront. Should the Phase 3 data for IgG4-RD prove positive, it has the potential to set the stage for addressing broader downstream indications.
Initial clinical results for Zenas BioPharma's primary candidate, obexelimab, appear promising. There's potential for this therapy to stand out in terms of safety and effectiveness within substantial inflammation and immunology-related markets. The anticipation of considerable stock appreciation is tied to upcoming Phase II/III developments in 2024 and 2025.
Zenas BioPharma is identified as a late clinical stage biotech firm with a focus on tackling inflammation and immunological challenges. The company's prime asset, obexelimab, is characterized as a 'first-in-class' with a unique inhibitory action for a range of B-cell mediated autoimmune conditions.
Zenas BioPharma's principal product, obexelimab, has the potential to lead its class as an anti-CD19xFcgammaRIIb bifunctional B cell-inhibiting antibody, with ongoing development targeting IgG4-related disease. The current market valuation of the company stands at approximately $480 million, and with several important clinical milestones expected in the next year and a half, there appears to be substantial room for growth in the company's value from its present position.
Here are the latest investment ratings and price targets for $Zenas BioPharma (ZBIO.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月8日，多家華爾街大行更新了$Zenas BioPharma (ZBIO.US)$的評級，目標價介於27美元至40美元。
摩根士丹利分析師Vikram Purohit首次給予買入評級，目標價40美元。
花旗分析師Yigal Nochomovitz首次給予買入評級，目標價27美元。
富瑞集團分析師Roger Song首次給予買入評級，目標價35美元。
Guggenheim分析師Yatin Suneja首次給予買入評級。
此外，綜合報道，$Zenas BioPharma (ZBIO.US)$近期主要分析師觀點如下：
Zenas BioPharma的obexelimab被視爲其產品組合中的重要資產，旨在解決炎症和免疫學範疇內的各種病況。主要適應症IgG4-RD處於前沿。如果對IgG4-RD的3期數據證明爲積極，將有可能爲解決更廣泛的下游適應症奠定基礎。
Zenas BioPharma的主力候選藥obexelimab的初步臨床結果看似令人鼓舞。這種療法在廣泛的炎症和免疫相關市場中有望在安全性和有效性方面脫穎而出。對2024年和2025年即將進行的II/III期發展存在可觀的股價升值預期。
Zenas BioPharma被認定爲一個專注於應對炎症和免疫挑戰的晚期臨床階段生物技術公司。該公司的主要資產obexelimab被形容爲'首創類'，具有針對一系列b細胞介導的自身免疫性症狀的獨特抑制作用。
Zenas BioPharma的主打產品obexelimab有望成爲其類別中的領導者，作爲一種針對CD19xFcgammaRIIb雙向作用b細胞抑制抗體，正在持續開發以應對IgG4相關疾病。該公司目前的市場估值約爲$48000萬，未來一年半預期有幾個重要臨床里程碑事件，從現有位置看來，公司價值增長空間可觀。
以下爲今日4位分析師對$Zenas BioPharma (ZBIO.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
